alexa Diagnostic Challenges In Lung Neuroendocrine Tumors
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

13th International conference on Pathology and Molecular Diagnosis
June 26-27, 2017 San Diego, USA

Mark Podberezin
University of Saskatchewan, Canada
ScientificTracks Abstracts: J Clin Exp Pathol
DOI: 10.4172/2161-0681-C1-034
Abstract
Neuroendocrine tumors (NET) of the lung constitute approximately 15% of all lung tumors, with small cell lung cancer (SCLC) accounting for 15% of invasive cancers. Many of those tumors have radiological and clinical presentation which is different from other pulmonary malignancies. In most cases, diagnosis could be established by core needle biopsy and, not uncommonly, SCLC is detected by endoscopic bronchial ultrasound fine needle aspiration (EBUS-FNA). Spectrum of lung NETs includes typical carcinoid (TC), atypical carcinoid (AC), SCLC and large cell neuroendocrine carcinoma (LCNEC). Morphological criteria, separating low grade from high grade NETs, include cellular atypia, mitotic rate, and presence or absence of necrosis. The question, which has been yet unanswered and which is addressed in the presentation, is whether the above NETs represent continuum from low to high grade tumors or they are biologically different. One of the major diagnostic challenges in pulmonary NETs is their grading on core needle biopsies (CNB). It has been shown that morphological features of NET, when diagnosed by CNB, could be significantly different from the ones on same tumor upon subsequent surgical resection. This could be partially due to marked crush and processing artifact which markedly affect evaluation of mitotic rate. Measurement of proliferative rate by immunohistochemical stain for Ki67 has been approved for grading of NET in the gastrointestinal tract, but is not universally accepted in pulmonary NET. However, it can be very helpful in evaluation of CNB with marked cautery and crush artifact. In addition, CNBs may not be representative of the entire lesion and can lead to diagnostic pitfalls which will be discussed in the presentation.
Biography

Mark Podberezin has completed his Medical School Degree (MD) and subsequent Clinical Hematology/Oncology training and PhD in Russia. Later, he did his Residency in Anatomic and Clinical Pathology at University of Illinois at Chicago and Hematopathology Fellowship at Texas Methodist Hospital in Houston. He is an Anatomic Pathologist (with special interest in Lung Pathology) and Hematopathologist at Royal University Hospital, University of Saskatchewan, Canada. He published 14 papers and presented at national, as well as international meetings.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords